Analyst consensus rating
Abeona Therapeutics Analyst Rating: Strong Buy
ABEO is rated Strong Buy by 7 analysts with a $18.86 target. As of 2026-08-27.
Direct answer
Abeona Therapeutics's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $18.86.
Forecast evidence checked August 27, 2026.
Get free Abeona Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.01
- Average price target
- $18.86
- High price target
- $28.00
- Low price target
- $14.00
- Low target gap
- +132.9%
- Target upside
- +213.8%
- High target gap
- +365.9%
- Target range width
- 232.9%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Abeona Therapeutics?
Abeona Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $18.86.
How far are Abeona Therapeutics's low and high targets from the recorded price?
The low target implies +132.9%, while the high target implies +365.9%.
How many analysts are included in Abeona Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is Abeona Therapeutics's target upside or downside calculated?
The average target of $18.86 is divided by the recorded price of $6.01, then one is subtracted to produce +213.8%. This does not guarantee a future return.
When was Abeona Therapeutics's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.